Selinexor inhibits XPO1 and has shown promising responses in multiple myeloma (8), acute myeloid leukemia (AML) (9, 10), and non-Hodgkin lymphoma (11) patients. The gene discussed is XPO1; the disease is acute myeloid leukemia.